[Update and interpretation of 2021 National Comprehensive Cancer Network (NCCN) "Clinical Practice Guidelines for Bone Tumors"].

{"article_title":"[Update and interpretation of 2021 National Comprehensive Cancer Network (NCCN) \"Clinical Practice Guidelines for Bone Tumors\"].","author":"Ni M","journal_title":"Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery","issn":"1002-1892","isbn":"","publication_date":"2019 Jun","volume":"35","issue":"9","first_page":"1186","page_count":"","accession_number":"34523287","doi":"10.7507\/1002-1892.202103073","publisher":"Hua xi yi ke da xue Fu shu di 1 yi yuan","doctype":"Journal Article","subjects":"Bone Neoplasms diagnosis; Bone Neoplasms epidemiology; Bone Neoplasms therapy; Giant Cell Tumors; Osteosarcoma; Sarcoma, Ewing; Humans; Neoplasm Recurrence, Local","interest_area":["Orthopedic"," Oncology"," Emergency Medicine"],"abstract":"The incidence of primary malignant bone tumors is low, and clinical cognition is insufficient. The establishment of diagnostic criteria is of great significance for prognosis of tumors. National Comprehensive Cancer Network (NCCN) regularly publishes \"Clinical Practice Guidelines for Bone Tumors\" to summarize the latest treatment progress of bone tumors. In the latest version of the guidelines released in November 2020, surgery is the main treatment for chondrosarcoma, chordoma, and giant cell tumor of bone, which can be combined with radiotherapy or targeted therapy. Ewing's sarcoma and osteosarcoma are treated by surgery combined with chemotherapy. Immunotherapy can be used to treat high-grade undifferentiated pleomorphic sarcoma. For recurrent tumors, surgery combined with radiotherapy, chemotherapy, and\/or targeted therapy can be used for control. The guidelines provide a reference for the standard treatment of bone tumors.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34523287&authtype=shib&custid=ns346513&group=main&profile=eds","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Ni M","Journal_Info":"Publisher: Hua xi yi ke da xue Fu shu di 1 yi yuan Country of Publication: China NLM ID: 9425194 Publication Model: Print Cited Medium: Print ISSN: 1002-1892 (Print) Linking ISSN: 10021892 NLM ISO Abbreviation: Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi Subsets: MEDLINE","Publication_Type":"Journal Article; Practice Guideline","Published_Date":"2021-09-15","Source":"Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery [Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi] 2021 Sep 15; Vol. 35 (9), pp. 1186-1191.","Languages":"Chinese","MeSH_Terms":"Bone Neoplasms*\/diagnosis , Bone Neoplasms*\/epidemiology , Bone Neoplasms*\/therapy , Giant Cell Tumors* , Osteosarcoma* , Sarcoma, Ewing*, Humans ; Neoplasm Recurrence, Local","Subjects":"Humans, Neoplasm Recurrence, Local, Bone Neoplasms diagnosis, Bone Neoplasms epidemiology, Bone Neoplasms therapy, Giant Cell Tumors, Osteosarcoma, Sarcoma, Ewing","Title_Abbreviations":"Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery","Volume":"35"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"34523287","RelevancyScore":"898","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"897.51220703125"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=34523287&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=34523287&authtype=shib&custid=ns346513&group=main&profile=eds"}